|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
To assess the potential use of this new PET tracer for tumor targeting, in vivo pretargeted PET imaging was performed in LS174T tumor-bearing mice pre-treated with a tetrazine-modified anti-TAG-72 monoclonal antibody (CC49).
|
31707309 |
2020 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Antibodies that target a single tumor antigen fail to cure stage IV cancer patients due to tumor heterogeneity and variable expression of antigen.
|
31812660 |
2020 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Lowering the barrier of immunosuppression by targeting the genetically stable tumor stroma presents opportunities to treat the tumor in a way that circumvents the complications of targeting a constantly mutating tumor with tumor antigen-directed therapies.
|
30804019 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescence.
|
30753335 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Thus, cancer therapy using an ER-targeting sequence linked to a tumor antigen holds promise for treating tumors by triggering strong immune reactions.
|
31598403 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
These protective effects of subcutaneous RA/CTS polyplex treatment were associated with the highest tumor antigen-specific humoral and cellular immune responses after tumor challenge, and with the greatest infiltration of CD4 helper T cell and CD8 T cell into the tumor tissues.
|
31847372 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In particular, the ideal tumor antigen should be able to elicit T cell and B cell responses, be specific for the tumor and be expressed at high levels on cancer cells.
|
31698088 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Anti-tumor activity of CW could be correlated with enhanced tumor antigen specific Th1 immune response observed in tumor draining lymph nodes.
|
30856391 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Treatment with anti-CD25 and radiation led to tumor eradication (57.1%, n = 4 of 7 mice), enhanced T-cell cytotoxicity compared with RT alone (CD4 effector T cells [Teff]: RT group mean = 5.37 [ 0.58] vs RT + αCD25 group mean =10.71 [0.67], P = .005; CD8 Teff: RT group mean = 9.98 [0.81] vs RT + αCD25 group mean =16.88 [2.49], P = .01) and induced tumor antigen-specific memory response (100.0%, n = 4 mice).
|
30863843 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
This tumor antigen-loaded nanoerythrosomes (nano-Ag@erythrosome) elicited antigen responses in vivo and, in combination with the anti-programmed death ligand 1 (PD-L1) blockade, inhibited the tumor growth in B16F10 and 4T1 tumor models.
|
31681841 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
TCR-transduced T-cells redirected to recognize the 5T4<sub>p17</sub> epitope from a broadly shared tumor antigen are of interest for future testing as a cellular immunotherapy strategy for HLA-A2<sup>+</sup> subjects with 5T4<sup>+</sup> tumors.
|
31686124 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The S-CM-HPAD NPs could effectively deliver the tumor antigen, DOX, and immunoadjuvant to the homotypic tumor by the homotypic targeting ability of the coated cell membrane.
|
30788951 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Tumor-associated cDC1s can transport tumor antigen to the draining lymph node and cross-present tumor antigens, resulting in priming and activation of cytotoxic T cells.
|
31143179 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Since there are also some challenges beyond the TME that are important for CAR function, we will also discuss and provide data about the improvement of CAR T cells trafficking and delivery to the tumor site and how to solve the problem of tumor antigen heterogeneity.
|
31161552 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Using adoptive transfer of tumor antigen-specific CD8 T cells, we demonstrate that T cells activated and expanded in the presence of E64FC26 control tumor growth better than vehicle-matched controls.
|
31779147 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Tumor antigen-specific T<sub>reg</sub>-derived TCRs resided in the tumor and in the circulation, suggesting that both T<sub>reg</sub> cell compartments may serve as a source for tumor-specific TCRs.
|
30635355 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Mechanistically, tumor cell-intrinsic RIG-I signaling induced caspase-3-mediated tumor cell death, cross-presentation of tumor-associated antigen by CD103<sup>+</sup> dendritic cells, subsequent expansion of tumor antigen-specific CD8<sup>+</sup> T cells, and their accumulation within the tumor tissue.
|
31519811 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
We also demonstrated that the hybrid nanocomposites successfully induce tumor antigen-specific cellular immunity and significantly inhibit tumor growth in vivo.
|
30809611 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In contrast, tumor dendritic cells (DC) are associated with tumor antigen uptake and T-cell priming.
|
31214174 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
However, the difficulty in harvesting a large number of tumor antigen-specific CTLs from the tumor patient is still a major obstacle we need to overcome.
|
31396937 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Tumor-associated antigen-specific cytotoxic T lymphocyte (TAA-CTLs)-based therapy was introduced and increasingly used clinically to kill tumor cells via tumor antigen activation.
|
31406473 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Our study shows that the tumor antigen CA19-9 secreted to the circulation can be used for sensitive detection of primary tumors and metastatic disease by immuno-PET.
|
31540979 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells.
|
31041975 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
More importantly, this two-pronged approach evoked tumor antigen-specific immune responses and the mice were resistant to another tumor rechallenge, finally, long-term survival was improved.
|
31476848 |
2019 |
|
LINC01194
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Here we introduce a novel approach in generating tumor antigen-specific CTLs from induced pluripotent stem cells (iPSCs) by using both in vitro and in vivo priming mechanisms for the tumor management in a murine melanoma model.
|
30465194 |
2019 |